Psoriasis is a chronic multi-systemic inflammatory skin disease affecting approximately 1% - 3% of the world population [1]. The global prevalence of psoriasis is estimated to between 0.09% and 11.43% [2], varying from 0.23% to 0.47% in Asian countries, and 2.3% to 3.2% in Europe and the United States [3], while prevalence by age varies from 0.02% to 0.21% in children to 0.14% and 2% in adults respectively. Its subtypes include psoriasis vulgaris, psoriasis pustular, psoriasis erythroderma and other relatively rare variants [4]. In China, p. vulgaris accounts for 82.6% - 97.9% of all cases, while p. pustular and p. erythroderma account for 0.69% - 2.17%, and 0% - 8.7% respectively [5]. Psoriasis is strongly mediated by genetic susceptibility, autoimmune disease, and environmental factors including infection, stress, and trauma. Its pathogenesis is closely related to the abnormal interaction among innate immunity, T cells, and keratinocytes [6]. Average age of onset is approximately 33 years, with two peaks of onset; the first at age 20 to 30 years and the second at age 50 to 60 years [7].

Psoriasis manifests as erythema, thickness, and scaling of the skin, with the skin area often appearing red, itchy, scaly, burning, and sore [8] [9]. Associated comorbidities include: autoimmune diseases, cardiovascular diseases, infections, cancers, metabolic diseases, mental diseases, and psoriatic arthritis [10]. Although the genetic predisposition, pathogenesis, and management of psoriasis are better known today, it still remains incurable [11], with treatment primarily focused on reducing symptoms and enhancing quality of life. Although psoriasis is difficult to treat, various attempts are being made to manage the condition. However, prognosis prediction remains poor, making it hard to evaluate disease severity and patients’ treatment progress. Recently systemic immune inflammatory index, has been explored as a biomarker for prognosis and severity prediction of psoriasis. Using the neutrophils, platelet, and lymphocyte, an index is calculated, that is then correlated to the severity and prognosis of the disease [8] [12].

Given the existing variations in how the different types of psoriasis present, with overlaps at certain points, it’s important to know the key clinical characteristics of each, and how they interact to influence the disease progression and severity. Therefore, in this study, we assessed the association between systemic immune inflammatory index and the clinical characteristics of each of the three types of psoriasis, in order to assess how it can be used to monitor prognosis and disease severity in each of them individually.

This was a retrospective study conducted at the First Hospital of Jilin University, in Chaoyang District, Changchun, Jilin, China, from January 2020 to August 2022. Patient data was retrospectively retrieved from the electronic medical database. Patient selection was limited to the availability of complete blood count (CBC) records as the key selection criterion. Patients without CBC results or incomplete results were excluded. A total of 85 patients had their records retrieved; these included 35 for psoriasis vulgaris, 26 for psoriasis pustular and 24 for psoriasis erythroderma. The study was conducted in accordance with the Declaration of Helsinki. Study protocol was approved by the First Hospital of Jilin University Research Ethics Committee and patint cosnet was waived since the data were retrospectively collected. Clinical data retrieved were: Patients’ age, gender, type of psoriasis diagnosed, body mass index, duration of the disease, family history of psoriasis, history of smoking, diabetes, and hypertension records. Laboratory data retrieved were: Complete blood count (CBC), C-reactive protein, Immunoglobulin E (IgE), Total cholesterol, Triglycerides and Low-density lipoprotein cholesterol.

Dysfunction of the immune system is the hallmark of psoriasis [13]. It is manifested as chronic inflammation that involves over proliferation of keratinocytes. In recent years, studies have shown that psoriatic plaques are infiltrated with immune cells and have increased vascularity of the dermis [14]. Whether its keratinocytes or immune cells that trigger the pathological inflammation associated with psoriasis is still unproven. However, psoriasis is generally known as a multisystem inflammatory disease, involving keratinocytes, cells of the immune system and other cells of the body [15] [16] [17] [18]. In the immune system neutrophils, lymphocytes and monocytes are known as the cellular makers of the immune system. To aid prognostic assessment of inflammatory conditions, studies have shown that these immune cells can be useful in clinical practice. As a result, various indices such as neutrophil-lymphocyte ratios (NLR), and platelet-lymphocyte ratios (PLR) have been developed. In psoriasis, NLR is an inexpensive and easily to obtain index that is used in combination with platelet count as systemic immune inflammation index (SII) to predict prognosis and asses severity of the disease [9]. In this study, we assessed the association between SII and the different subtypes of psoriasis in 85 psoriasis patients. We determined whether SII was associated with severity and duration of disease, and other important clinical characteristics of patients with psoriasis, in the different sub types of the diseases.

By demographics, majority of our study population were males, 48 (56.47%), compared to 37 (43.53%) females, however psoriasis in general affects both men and women equally [7]. On average, patients with psoriasis erythroderma were much older than those with p. pustular and p. vulgaris. While there is no empirical evidence to show that onset of the different types of psoriasis are associated with age, studies show that psoriasis has 2 peaks of onset, the first at age 20 to 30 years and the second at age 50 to 60 years [7]. The mean age of affected patients were 47.3 ± 15.3 years for p. vulgaris, 45.3 ± 14.6 for p. pustular and 57.1 ± 11.7 years for p. erythroderma. A 2012 study in China revealed that the two peak onset ages of psoriasis among Chinese was at 20 - 29 years, and at 40 - 49 years, with approximately 68% of patients developing the disease before age 40 years [19].

In our study, 49 (57.6%) of the patients had Psoriasis for less than 10 years, while 36 (42.4%) had the disease for more than 10 years, and psoriasis vulgaris was the most common diagnosis, 35 (41.2%), followed by Psoriasis pustular, 26 (30.6%) and then Psoriasis erythroderma (28.2%). This is consistent with a recent epidemiological study which revealed that p. vulgaris accounts for 82.6% - 97.9% of all psoriasis in China, with p. pustular and p. erythroderma accounting for 0.69% - 2.17%, and 0% - 8.7% respectively [5]. In terms of total white blood cells count, and other white cell indices (neutrophils, lymphocytes, and monocytes), p. pustular had consistently higher counts than all the other types. Even platelet count was higher in p. pustular than in the other sub types. This is consistent with a study by Liu et al. [20] who also noticed marked leukocytosis in p. pustular than the rest. The leukocytosis seen in p. pustular is sometimes associated with taking drugs for skin disease such as terbinafine [21], or the anti-cancer drug pembrolizumab [22]. However, our patients were not on any of these drugs, and so the cause of the mild leukocytosis remained unknown.

Considering the other blood biomarkers, mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly higher in psoriasis vulgaris (p < 0.01, and p < 0.001) than pustular and erythroderma, despite all of them being within the normal ranges. C-reactive protein on the other hand was 2 - 3 times above the upper limit of the reference range in psoriasis pustular and psoriasis erythroderma, and was significantly higher in psoriasis erythroderma (p < 0.001), than the rest. Strong associations have already been reported between psoriasis and cardiovascular diseases, and so increase in cholesterol is constantly seen among psoriasis patients [23]. C-reactive protein meanwhile is a predictor of cardiovascular disease in psoriasis [24], and an indicator of SII [9]. According to our results, p. pustular and p. erythroderma had dramatic rise in C-reactive protein, which would indicate increased risk for CVD in these patients. However, whether C-reactive protein is a good predictor of SII is still controversial; according to Sokolova et al. [25], C-reactive protein was not elevated in 105 patients with psoriasis assessed, neither was it elevated among the subgroups of psoriasis. Therefore, further large-scale studies are needed to confirm the role of C-reactive protein in predicting SII.

Previous studies have already demonstrated that SII is higher in psoriasis patients compared to normal individuals [9] [25]. However, this is the first study to determine the association between SII and the different types of psoriasis. In our findings, SII was significantly higher in p. pustular (p < 0.01), that the other subtypes of psoriasis. There was no association between SII and duration of psoriasis in any of the subtypes. When determined by other comorbidities, a significant relationship was noted between SII and hypertension in p. pustular patients (p < 0.05), while smoking, diabetes and others were non-significant. This result is consistent with previous studies that demonstrated association between psoriasis and cardiovascular diseases [26] [27], however, it is the first study to show an association between SII and a cardiovascular disease in p. pustular as a subtype of psoriasis. Looking at our study as a whole, there appears to be a relationship between SII and p. pustular whereas no relationship exists with p. vulgaris and p. erythroderma.

In summary, this study demonstrated that systemic immune inflammatory index (SII) is significantly higher in psoriasis pustular than other subtypes of psoriasis. It further demonstrated that an association existed between hypertension and SII in psoriasis pustular patients. However, there was no relationship between SII and duration of psoriasis or other clinical characteristics such as diabetes, family history and history of smoking. C-reactive protein was significantly upregulated in both psoriasis pustular and erythroderma but not vulgaris, while leukocytosis was observed in psoriasis pustular. These findings suggest a possible association between SII and p. pustular that should be investigated in an independent study.

Salah Hassan Ibrahim conducted data analysis and manuscript drafting. Guan mengqi conducted data collection. Li Shanshan conceptualized the study and supervised the entire process. All authors read and approved the final manuscript.

This study was supported by the National Natural Science Foundation of China (Grant No. 82073454).

All authors declare that there was no conflict of interest.

Ibrahim, S.H., Guan, M.Q. and Li, S.S. (2022) Systemic Immune Inflammatory Index Is Associated with Pustular Psoriasis: A Single Center Retrospective Study. Journal of Cosmetics, Dermatological Sciences and Applications, 12, 174-186. https://doi.org/10.4236/jcdsa.2022.124015